The Xolair Pregnancy Registry (EXPECT): Design of an Observational Study of Safety of (Omalizumab) During Pregnancy in Women With Asthma

被引：0
|
作者：
Namazy, J. [1 ]
Miller, M. K. [2 ]
Wang, V [2 ]
Gershman, A. [2 ]
Andrews, E. [3 ]
机构：
[1] Scripps Clin, San Diego, CA USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] RTI Hlth Solut, Res Triangle Pk, NC USA
来源：
BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY | 2011年 / 91卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：387 / 387
页数：1
相关论文
共 50 条
  • [1] The Xolair Pregnancy Registry (Expect): Design Of An Observational Study Of Safety Of (Omalizumab) During Pregnancy In Women With Asthma
    Namazy, J. A.
    Miller, M. K.
    Wang, V.
    Gershman, A.
    Andrews, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [2] The Xolair Pregnancy Registry (EXPECT): An Observational Study of the Safety of Omalizumab during Pregnancy in Women with Asthma
    Namazy, Jennifer
    Miller, Mary K.
    Wang, Vivian
    Gershman, Ari
    Andrews, Elizabeth
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S55 - S56
  • [3] The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy
    Namazy, Jennifer
    Cabana, Michael D.
    Scheuerle, Angela E.
    Thorp, John M., Jr.
    Chen, Hubert
    Carrigan, Gillis
    Wang, Yan
    Veith, Joachim
    Andrews, Elizabeth B.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : 407 - 412
  • [4] The Xolair Pregnancy Registry (EXPECT): Perinatal outcomes among pregnant women with asthma treated with omalizumab (Xolair) compared against those of a cohort of pregnant women with moderate-to-severe asthma
    Namazy, Jennifer A.
    Blais, Lucie
    Andrews, Elizabeth B.
    Scheuerle, Angela E.
    Cabana, Michael D.
    Thorp, John M.
    Veith, Joachim H.
    Umetsu, Dale T.
    Sun, Diana
    Kaufman, Derrick G.
    Covington, Deborah L.
    Mukhopadhyay, Santanu
    Fogel, Robert B.
    Lopez-Leon, Sandra
    Spain, Vic
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB103 - AB103
  • [5] The Xolair Pregnancy Registry (EXPECT): Perinatal Outcomes among Pregnant Women with Asthma Treated with Omalizumab (Xolair) Compared against Those of a Cohort of Pregnant Women with Moderate-to-Severe Asthma
    Namazy, J.
    Blais, L.
    Andrews, E. B.
    Scheuerle, A. E.
    Cabana, M. D.
    Thorp, J. M.
    Veith, J. H.
    Umetsu, D.
    Sun, D.
    Kaufman, D. G.
    Convington, D. L.
    Mukhopadhyay, S.
    Fogel, R.
    Lopez-Leon, S.
    Spain, V
    BIRTH DEFECTS RESEARCH, 2019, 111 (09): : 481 - 481
  • [6] Safety outcomes among infants exposed to Omalizumab via breastfeeding: Results from the Xolair pregnancy registry (EXPECT)
    Leon, Sandra Lopez
    Kaufman, D. G.
    Howard, M.
    Mukhopadhyay, S.
    Fogel, Robert
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 374 - 375
  • [7] EXPECT Enrollment: Impact of Recruitment Strategy on Enrollment in the Xolair® Pregnancy Registry
    Covington, Deborah
    Wang, Vivian
    Carrigan, Gillis
    Hurst, Nicole
    Veith, Joachim
    Chen, Hubert
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 148 - 149
  • [8] Pregnancy and infant outcomes among pregnant women with Chronic Spontaneous Urticaria (CSU) treated with omalizumab: a descriptive analysis from the EXPECT pregnancy registry
    Namazy, Jennifer
    Scheuerle, Angela
    Spain, Vic
    Janampally, Pranathi
    Ahmed, Ayesha
    Gupta, Sachin
    Holweg, Cecile
    Mumneh, Nayla
    Radojicic, Cristine
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB145 - AB145
  • [9] The safety of asthma medications during pregnancy
    Kallen, Bengt
    EXPERT OPINION ON DRUG SAFETY, 2007, 6 (01) : 15 - 26
  • [10] Triptan safety during pregnancy: a Norwegian population registry study
    Kateřina Nezvalová-Henriksen
    Olav Spigset
    Hedvig Nordeng
    European Journal of Epidemiology, 2013, 28 : 759 - 769
12345